Funding R&D through the 28th Series of Stock Acquisition Rights
First written in FY2024. 1 of 2 entries say "Achieved", first in FY2025-H1. Latest entry: FY2025-H1.
2 other companies' latest entry also says "Achieved".
- FY2025-H1AchievedAnnual report
「Cumulative number of such convertible bonds with stock acquisition rights, etc., with exercise price adjustment clauses exercised as of the end of the interim accounting period (units): 29,000. Cumulative number of shares delivered as of the end of the interim accounting period: 2,900,000. Cumulative amount of funds raised as of the end of the interim accounting period (¥ thousand): 960,515.」
Exercise of all 29,000 of the 28th Series of Stock Acquisition Rights was completed on a cumulative basis, resulting in the delivery of 2,900,000 shares and the raising of ¥960,515 thousand. - FY2024First statedAnnual report
「Pursuant to a resolution at a meeting of the Board of Directors held on 20 February 2024, we issued 29,000 of the 28th Series of Stock Acquisition Rights, with Barclays Bank PLC as the allottee. These stock acquisition rights represent a potential 2,900,000 shares.」
The company issued the 28th Series of Stock Acquisition Rights with Barclays Bank PLC as the allottee and introduced a financing measure to fund research and development expenses and working capital for PPMX-T004 and new pipeline programs. The exercise period ran from 8 March 2024 to 9 March 2026, and 106,400 shares were exercised during the fiscal year.